Latest Savient Pharmaceuticals Stories
Acquisition is highlighted by KRYSTEXXA® (pegloticase), the only product approved for the treatment of refractory chronic gout GLENDALE, Wis., Jan. 10, 2014 /PRNewswire/ -- Crealta Pharmaceuticals LLC ("Crealta"), a new specialty pharmaceutical company, announced today the completion of the acquisition of substantially all of the assets of Savient Pharmaceuticals, Inc. ("Savient"). Crealta previously announced the winning of an auction for these assets, the signing of a definitive...
- Boughs or branches.
- Warbling of birds in trees.